Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lundbeck To Buy Chelsea Therapeutics

by Rick Mullin
May 12, 2014 | A version of this story appeared in Volume 92, Issue 19

Lundbeck, the Danish drug firm specializing in neurological and brain diseases, has agreed to acquire Charlotte, N.C.-based Chelsea Therapeutics for $530 million up front. The firm will pay Chelsea shareholders an additional $128 million if Chelsea’s FDA-approved Northera meets unspecified commercial milestones by 2017. Northera is a treatment for light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by autonomic failure, a condition associated with Parkinson’s disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.